Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers

Next Previous
X
Search
Trial Profile

An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vemurafenib (Primary) ; Cetuximab
  • Indications Anaplastic astrocytoma; Cholangiocarcinoma; Colorectal cancer; Glioblastoma; Glioma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms VE-BASKET
  • Sponsors Roche

    • Most Recent Events

    • 23 Oct 2018 Results (n=24) of Glioma cohort assessing the safety and efficacy of vemurafenib, published in the Journal of Clinical Oncology.
    • 06 Nov 2017 According to a Genentech media release, the U.S. Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation. The approval is based on data from this study.
    • 17 Oct 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top